Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT07003425

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

Led by Apogee Therapeutics, Inc. · Updated on 2026-04-30

350

Participants Needed

45

Research Sites

237 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948). The LTE study will consist of 3 periods: 1) Screening Visit will coincide with the last visit of the Maintenance Period in the Parent Study 2) Extended Treatment Period 3) Post-treatment Follow-up Period. This study will be conducted in participants with atopic dermatitis (AD) who completed the Treatment Period in a prior APG777 study and who, in the opinion of the Investigator, would benefit from long-term treatment with APG777.

CONDITIONS

Official Title

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Completed the treatment period in a prior APG777 study and were compliant with the study protocol
  • Considered by the Investigator to benefit from long-term treatment with APG777
  • Use the same non-prescription non-medicated emollient or moisturizer from the last day of the Parent Study throughout the LTE study
Not Eligible

You will not qualify if you...

  • Developed an adverse event during the Parent Study that may make continued APG777 treatment unsafe
  • Terminated early or permanently discontinued the study drug during the Parent Study
  • Used any prohibited medications from the Parent Study through the LTE study screening visit
  • Have dermatologic conditions or comorbidities that could confuse the AD diagnosis or interfere with study assessments
  • Additional protocol-defined inclusion or exclusion criteria may apply

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 45 locations

1

Investigational Site

Fountain Valley, California, United States, 92708

Actively Recruiting

2

Investigational Site

Los Angeles, California, United States, 90024

Actively Recruiting

3

Investigational Site

Coral Gables, Florida, United States, 33134

Actively Recruiting

4

Investigational Site

Jacksonville, Florida, United States, 32256

Actively Recruiting

5

Investigational Site

Margate, Florida, United States, 33063

Actively Recruiting

6

Investigational Site

Douglasville, Georgia, United States, 30135

Actively Recruiting

7

Investigational Site

Skokie, Illinois, United States, 60077

Actively Recruiting

8

Investigational Site

Bowling Green, Kentucky, United States, 42101

Actively Recruiting

9

Investigational Site

Detroit, Michigan, United States, 48202

Actively Recruiting

10

Investigational Site

Troy, Michigan, United States, 48084

Actively Recruiting

11

Investigational Site

New York, New York, United States, 10023

Actively Recruiting

12

Investigational Site

Wilmington, North Carolina, United States, 28403

Actively Recruiting

13

Investigational Site

Boardman, Ohio, United States, 44512

Actively Recruiting

14

Investigational Site

Mason, Ohio, United States, 45040

Actively Recruiting

15

Investigational Site

Portland, Oregon, United States, 97223

Actively Recruiting

16

Investigational Site

Pittsburgh, Pennsylvania, United States, 15213

Actively Recruiting

17

Investigational Site

Charleston, South Carolina, United States, 29425

Actively Recruiting

18

Investigational Site

Nashville, Tennessee, United States, 37215

Actively Recruiting

19

Investigational Site

Dallas, Texas, United States, 75230

Actively Recruiting

20

Investigational Site

Frisco, Texas, United States, 75235

Actively Recruiting

21

Investigational Site

San Antonio, Texas, United States, 78213

Actively Recruiting

22

Investigational Site

Calgary, Alberta, Canada, T2J 7E1

Actively Recruiting

23

Investigational Site

Edmonton, Alberta, Canada, T5J 3S9

Actively Recruiting

24

Investigational Site

Fredericton, Brunswick, Canada, E3B 1G9

Actively Recruiting

25

Investigational Site

Ajax, Ontario, Canada, L1S 7K8

Actively Recruiting

26

Investigational Site

Markham, Ontario, Canada, L3P 1X3

Actively Recruiting

27

Investigational Site

Mississauga, Ontario, Canada, L4Y 4C5

Actively Recruiting

28

Investigational Site

Peterborough, Ontario, Canada, K9J 5K2

Actively Recruiting

29

Investigational Site

Toronto, Ontario, Canada, M3B 0A7

Actively Recruiting

30

Investigational Site

Toronto, Ontario, Canada, M4E 2Y9

Actively Recruiting

31

Investigational Site

Toronto, Ontario, Canada, M4W 2N4

Actively Recruiting

32

Investigational Site

Montreal, Quebec, Canada, H2X 2V1

Actively Recruiting

33

Investigational Site

Québec, Quebec, Canada, G1V 4X7

Actively Recruiting

34

Investigational Site

Blankenfelde-Mahlow, Brandenburg, Germany, 15831

Actively Recruiting

35

Investigational Site

Wroclaw, Lower Silesian Voivodeship, Poland, 50-450

Actively Recruiting

36

Investigational Site

Wroclaw, Lower Silesian Voivodeship, Poland, 51-503

Actively Recruiting

37

Investigational Site

Lublin, Lublin Voivodeship, Poland, 20-573

Actively Recruiting

38

Investigational Site

Warsaw, Masovian Voivodeship, Poland, 01-595

Actively Recruiting

39

Investigational Site

Warsaw, Masovian Voivodeship, Poland, 02-482

Actively Recruiting

40

Investigational Site

Gdansk, Pomeranian Voivodeship, Poland, 80-546

Actively Recruiting

41

Investigational Site

Katowice, Silesian Voivodeship, Poland, 40-600

Actively Recruiting

42

Investigational Site

Sosnowiec, Silesian Voivodeship, Poland, 41-218

Actively Recruiting

43

Investigational Site

Szczecin, West Pomeranian Voivodeship, Poland, 71-500

Actively Recruiting

44

Investigational Site

Krakow, Woj. Małopolskie, Poland, 30-727

Actively Recruiting

45

Investigational Site

Lodz, Poland, 90-237

Actively Recruiting

Loading map...

Research Team

S

Study Director

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

NON_RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis | DecenTrialz